Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Twelve-months Extension Study to Explore the Long-Term Safety and Efficacy of Subcutaneous Administration of GV1001 1.12 mg/Day in Patients With Progressive Supranuclear Palsy Who Completed Study GV1001-PSP-CL2-011

NCT06235775 is registered in ClinicalTrials.gov with GemVax & Kael as lead sponsor.

NCT NCT06235775
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06235775 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Twelve-months Extension Study to Explore the Long-Term Safety and Efficacy of Subcutaneous Administration of GV1001 1.12 mg/Day in Patients With Progressive Supranuclear Palsy Who Completed Study GV1001-PSP-CL2-011
Lead sponsor
GemVax & Kael
Phase
Phase 2
Overall status
Completed
Start date
December 12, 2023
Completion date
September 1, 2025
Enrollment
67 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

progressive supranuclear palsy